Immunosuppressants FK506 and cyclosporin A inhibit neurotoxicity of N-methyl-D-aspartate in primary cortical cultures, while having no effect on quisqualate-and kainate-mediated neurotoxicity. Rapamycin completely reverses the neuroprotective effect of FK506. Both FK506 and cyclosporin A inhibit NMDA-elicited/nitric oxide-mediated increases in cGMP levels in cortical cultures. FK506 has no effect on sodium nitroprusside-induced increases in cGMP. In a stably transfected human kidney 293 cell line overexpressing the gene encoding nitric oxide synthase [L-arginine, NADPH:oxygen oxidoreductase (nitric oxide-forming), EC 1.14.13.39], FK506 inhibits the calcium ionophore A23187, stimulated increases in nitrite (a breakdown product of nitric oxide), and potentiates phorbol ester-mediated inhibition of nitrite formation. FK506-mediated inhibition of nitric oxide formation is completely reversed by rapamycin. Calcineurin dephosphorylates protein kinase C-mediated phosphorylation of nitric oxide synthase. FK506 prevents the calcineurinmediated dephosphorylation of nitric oxide synthase and thereby diminishes the enzyme's catalytic activity. These data establish nitric oxide synthase as a calcineurin substrate. Nitric oxide synthase catalytic activity is regulated by the phosphorylation state of the enzyme. Enhanced phosphorylation of nitric oxide synthase diminishes catalytic activity, and dephosphorylation (through activation of calcineurin) enhances catalytic activity. The neuroprotective effect of FK506 and cyclosporin A presumably involves the inhibition of calcineurin, preventing the dephosphorylation of nitric oxide synthase and its subsequent activation.
activity. The neuroprotective effect of FK506 and cyclosporin A presumably involves the inhibition of calcineurin, preventing the dephosphorylation of nitric oxide synthase and its subsequent activation.
Besides their roles in the immune system, the immunophilins cyclophilin and FK506 binding protein (FKBP) are highly concentrated in the brain in discrete neuronal structures where they are colocalized with the Ca2+-activated phosphatase calcineurin (1). Liu et al. (2) demonstrated that very low concentrations of FK506 and cyclosporin A, which bind to FKBP and cyclophilin, respectively, inhibit calcineurin, and we (1) showed that both drugs enhance the phosphorylation of a number of proteins in the brain. Glutamate neurotoxicity acting via N-methyl-D-aspartate (NMDA) receptors is implicated in neuronal damage associated with cerebral infarcts and neurodegenerative diseases (3) (4) (5) . In primary cerebral cortical cultures (6, 7) , in hippocampal slices (8) (9) (10) , and in animal models of focal ischemia (11) , NMDA toxicity is mediated at least in part by nitric oxide (NO) because this toxicity is blocked by inhibitors of NO synthase [NOS; L-arginine, NADPH:oxygen oxidoreductase (nitric oxideforming), EC 1.14.13.391. Phosphorylation of NOS by protein kinase C (PKC) (12) , cAMP-dependent protein kinase, Ca2+/ The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.
calmodulin-dependent protein kinase, and cGMP-dependent protein kinase (J.L.D., J.P.S., T.M.D., and S.H.S., unpublished data) all inhibit its catalytic activity. Accordingly, we wondered whether enhanced phosphorylation associated with FK506 treatment might alter neurotoxicity. In the present study we demonstrate that low concentrations of FK506 and cyclosporin A markedly diminish NMDA neurotoxicity, enhance the phosphorylation of NOS, inhibit NOS catalytic activity, and inhibit NO-mediated increases in cGMP.
MATERIALS AND METHODS
Cell Cultures. Primary neuronal cultures from cortex were prepared from fetal Sprague-Dawley rats, gestation day 13-14. After dissection, the cells were dissociated by trituration, counted, and plated in 15-mm multiwell (Nunc) plates coated with polyornithine at a density of 3-4 x 105 cells per well. Proliferation of nonneuronal cells was inhibited by applying 10 ug of 5-fluoro-2'-deoxyuridine 4 days after plating for a total of 3 days. Neurons were maintained in modified Eagle's medium (MEM) containing 5% (vol/vol) horse serum and 2 mM glutamine in humidified 8% C02/92% air at 370C.
Medium was changed twice a week. Mature neurons (>21 days in culture) were used in all experiments. In these cultures neurons are -.70-90% of the total number of cells as assessed by neuron-specific enolase and glial fibrillary acidic protein immunohistochemistry (unpublished observation).
Cytotoxicity. Neurotoxicity was determined by exposing the neurons to the various test solutions as described (6 
(TBS)
. The cells were immediately lysed by addition of 1% Triton X-100/0.5% deoxycholate/0.2% SDS/50 mM Tris-HCl/150 mM NaCl/1 mM Na2EDTA, pH 7.4 (lysis buffer) at 4°C. After a 10-min centrifugation at 10,000 x g, the cell supernatant was mixed with an equal volume of TBS and 5 ,g of affinity-purified NOS IgG directed against a synthetic peptide (Cys-Glu-Asn-Thr-Phe-Gly-Val-Gln-Gln-Ile-GlyPro-Asn-Val) corresponding to the N-terminal 2-13 amino acid residues of the NOS protein (13) . After a 2-hr incubation with the anti-NOS antibody, formalin-fixed Staphylococcus aureus bearing protein A was added for an additional 60 min at 4°C. Immunocomplexes were then centrifuged at 10,000 x g for 10 min, and the pellet was washed three times in lysis buffer. Immunoprecipitated NOS was resolved by PAGE on 3.5-17% linear gradient gels in Laemmli buffers; duplicate gels were either electroblotted to nitrocellulose or dried, and autoradiograms were prepared. The level of phosphorylation was quantitated by densitometry using the Eagle Eye Imaging System (Stratagene) and National Institutes of Health Image 1.44 software (14, 15 
RESULTS
NMDA Neurotoxicity is Dependent on Calcineurin Activation. We monitored neurotoxicity in primary cerebral cortical neuronal cultures in which a 5-min exposure to NMDA results in death of about 80% of the neurons when observed 24 hr later (6) . Treatment of the cultures with FK506 for 5 min prior to application of NMDA and during the 5 min of NMDA application provided marked protection from neurotoxicity ( Table 1) . As little as 25 nM FK506 provided significant protection, while 50% protection was evident between 25-100 nM. To ascertain whether FK506 exerted its protective effects by interacting with its receptor FKBP, we examined the effect of rapamycin, which binds to FKBP and blocks the effects of FK506 (2, (16) (17) (18) . Rapamycin at 1 ,uM completely reversed the effects of FK506. The immunosuppressants FK506 and cyclosporin A exert a number of different actions but share the ability to inhibit the Ca2+-dependent phosphatase activity of calcineurin (2, (19) (20) (21) . Cyclosporin A at 1 ,uM also protected against NMDA neurotoxicity, suggesting that the protection involved inhibition of calcineurin (Table 1) . When applied by themselves, in the absence of NMDA, 500 nM FK506, 1 ,uM cyclosporin A, and 1 ,M rapamycin had no effect on neuronal viability (data not shown). Moreover, 500 nM FK506 had no effect on NMDA-elicited Ca2+ currents in these cultures (data not shown).
Earlier we showed that NMDA neurotoxicity in these cultures is prevented by inhibition of NO formation, suggesting that NO plays a role in NMDA neurotoxicity (6, 7, 22) . (Fig. 1) and that 100 nM FK506 together with FKBP completely blocked the dephosphorylation (Fig. 1) (Fig. 2) . Following treatment with TPA, NOS showed a substantial increase in phosphorylation. The addition of 100 nM FK506 to TPA significantly enhanced TPA-induced phosphorylation, establishing NOS as a calcineurin substrate (Fig. 2 ). Attempts to demonstrate a similar phenomenon in intact cortical cultures or cortical slices were inconsistent, probably because of the low abundance of NOS protein in these areas (data not shown). FK506 Inhibits NOS Catalytic Activity. To ascertain whether the enhanced phosphorylation of NOS by FK506 diminishes functional NO activity, we monitored cGMP levels in the neuronal cultures (Table 2 ). In brain slices (24) (25) (26) and neuronal cultures (6), NMDA increased cGMP levels several fold, and the increase was prevented by NOS inhibitors (6, 24) . In these cultures 100 nM FK506 reduced the NMDA stimulation of cGMP levels by z80%. Cyclosporin A at 1 ,uM also diminished the NMDA stimulation of cGMP. Evidence that FK506 is acting at the level of NOS rather than blocking the effects of generated NO on guanylyl cyclase came from our experiments showing that the stimulation of cGMP levels by sodium nitroprusside, which generates NO, was not significantly affected by FK506.
Since cGMP measurements are only an indirect measure of NO formation and current methods of measuring NO formation and NOS catalytic activity are insensitive in cortical cultures, we assessed the effects of FK506 on NOS catalytic activity in intact 293.NOS cells (Table 3) . In intact 293.NOS cells, NOS catalytic activity was directly measured by quantitation of NO-, a breakdown product of NO, after the addition of the calcium ionophore A23187 (10 ,uM) ( Table 3) . Treatment of the cells with 500 nM FK506 reduced A23187-stimulated catalytic activity by 33%, and treatment with 100 nM TPA reduced A23187-stimulated activity by 50%. The combination of FK506 and TPA was additive, reducing A23187-stimulated NOS catalytic activity by 63%. Rapamycin at 1 uM completely reversed the effect of FK506, establishing that FK506 reduces NOS activity by interacting with FKBP.
DISCUSSION
Our findings indicate that the immunophilins may play a role in regulating NMDA-mediated glutamate neurotoxicity. Evidence includes the potent neuroprotective effect of FK506, which is receptor-mediated because it is blocked by rapamycin, and the similar protective effect provided by cyclosporin A. The protective effects of FK506 appear to involve functional inhibition of NOS by blocking its dephosphorylation. Thus, NOS is a calcineurin substrate whose PKCmediated phosphorylation is enhanced by FK506. PKC phosphorylation of NOS does inhibit its enzymatic activity (12) (J.L.D., J.P.S., T.M.D., and S.H.S., unpublished data), although others have shown that PKC enhances NOS activity (27) . FK506 may also inhibit the dephosphorylation of Ca2+/ calmodulin-dependent protein kinase or cyclic nucleotidedependent phosphorylation sites. The neuroprotective concentrations of FK506 diminish NMDA enhancement of cGMP levels, which is NO-mediated (22, 25, 26) . The extent of inhibition of cGMP increased by FK506 is about the same as the inhibition produced by 100 ,uM nitroarginine (6) , which correlates with the extent to which these two drugs protect against neurotoxicity (data not shown; ref. 6). The observation that FK506 fails to block quisqualate and kainate neurotoxicity further supports a role for NO in FK506's neuroprotective effects because quisqualate and kainate neurotoxicities do not involve NO (6, 22) .
Besides inhibiting calcineurin, FK506 acts at other sites including steroid receptors (28, 29) , FKBP25 (30, 31) , and other unidentified targets such as those related to FKBP13 (32) . Cyclosporin A inhibits calcineurin activity but does not exert these other actions. The fact that cyclosporin A as well as FK506 protects against NMDA toxicity reinforces the notion that inhibition of calcineurin is responsible for neuroprotection. Though our evidence strongly supports the hypothesis that FK506 neuroprotection involves inhibition of NOS, the fact that FK506 increases phosphorylation of numerous proteins indicates that other mechanisms may also play some role.
A model that emerges from these findings is that glutamate, acting via NMDA receptors, stimulates Ca2+ iniflux into cells (Fig. 3) . The Ca2+ binds to calmodulin which activates NOS, generating NO. The NOS-containing cells are resistant to neurotoxicity (7, 35) (33, 34) . Ca2+ binds to calmodulin (CAM), activating NOS. The generated NO diffuses to adjacent cells to activate guanylate cyclase and increase intracellular cGMP levels (25) . If sufficient quantities of NO are produced, adjacent cells die via undefined mechanisms (22) , whereas neurons that produce NO are uniquely resistant (35) . NOS catalytic activity is inhibited by PKCmediated phosphorylation (12) . Activation of PKC by glutamate acting on metabotropic glutamate receptors (36) (37) (38) or by other mechanisms would diminish NOS catalytic activity. Ca2+ entry activates calcineurin, which dephosphorylates and activates NOS. FK506, complexed to FKBP, binds to calcineurin, inhibiting its phosphatase activity. This prevents the dephosphorylation of NOS, thus decreasing NOS catalytic activity. With lowered NO production adjacent neurons remain viable.
dephosphorylated by calcineurin, a Ca2+/calmodulindependent phosphatase, while FK506 bound to FKBP inhibits calcineurin activity, thereby increasing NOS phosphorylation and diminishing its catalytic activity. The resultant decreased formation of NO after FK506 treatment inhibits neurotoxicity.
Physiologic stimulation of neuronal NOS by glutamatergic transmission appears to involve direct activation of the enzyme by Ca2+ entering NMDA-regulated channels (22, 24, 26) . Greengard and colleagues (39, 40) (41) . Interestingly, in a study of liver transplantation, 7 of 14 patients receiving cyclosporin A showed global cerebral ischemia, while none of the 14 patients receiving FK506 showed such alterations (42) . This suggests that drugs that interact with immunophilins and enter the brain may have therapeutic potential.
